PMID- 35157100
OWN - NLM
STAT- MEDLINE
DCOM- 20220826
LR  - 20221004
IS  - 1439-099X (Electronic)
IS  - 0179-7158 (Print)
IS  - 0179-7158 (Linking)
VI  - 198
IP  - 9
DP  - 2022 Sep
TI  - Results of sole postoperative interstitial, high-dose-rate brachytherapy of T1-2 
      tongue tumours.
PG  - 812-819
LID - 10.1007/s00066-022-01901-w [doi]
AB  - PURPOSE: To describe the results of treating tongue cancer patients with single 
      postoperative interstitial, high-dose-rate (HDR) brachytherapy (BT) after 
      resection. METHODS: Between January 1998 and April 2019, 45 patients with 
      squamous cell histology, stage T1-2N0-1M0 tongue tumours were treated by surgery 
      followed by a single HDR BT in case of negative prognostic factors (close or 
      positive surgical margin, lymphovascular and/or perineural invasion). The average 
      dose was 29 Gy (range: 10-45 Gy) and rigid metal needles were used in 11 (24%) 
      and flexible plastic catheters in 34 cases (76%). Survival parameters, toxicities 
      and the prognostic factors influencing survival were analysed. RESULTS: During 
      a mean follow-up of 103 months (range: 16-260 months) for surviving patients, the 
      10-year local and regional control (LC, RC), overall survival (OS), and 
      disease-specific survival (DSS) probabilities were 85, 73, 34 and 63%, 
      respectively. The incidence of local grade 1, 2 and 3 mucositis was 23, 73 and 
      4%, respectively. As a serious (grade 4), late side effect, soft tissue necrosis 
      developed in 3 cases (7%). In a univariate analysis, there was a significant 
      correlation between lymphovascular invasion and RC (p = 0.0118) as well as 
      cervical recurrence and DSS (p < 0.0001). CONCLUSION: Sole postoperative HDR 
      brachytherapy can be an effective method in case of negative prognostic factors 
      in the treatment of early, resectable tongue tumours. Comparing the results of 
      patients treated with postoperative BT to those who were managed with surgery or 
      BT alone known from the literature, a slightly more favourable LC can be achieved 
      with the combination therapy, demonstrating the potential compensating effect of 
      BT on adverse prognostic factors, while the developing severe, grade 4 toxicity 
      rate remains low.
CI  - (c) 2022. The Author(s).
FAU - Takacsi-Nagy, Zoltan
AU  - Takacsi-Nagy Z
AUID- ORCID: 0000-0002-3261-0271
AD  - Centre of Radiotherapy, National Institute of Oncology, Rath Gyorgy St. 7-9, 
      1122, Budapest, Hungary. takacsi@oncol.hu.
AD  - Department of Oncology, Semmelweis University, Budapest, Hungary. 
      takacsi@oncol.hu.
FAU - Ferenczi, Ors
AU  - Ferenczi O
AD  - Centre of Radiotherapy, National Institute of Oncology, Rath Gyorgy St. 7-9, 
      1122, Budapest, Hungary.
FAU - Major, Tibor
AU  - Major T
AUID- ORCID: 0000-0002-4672-6910
AD  - Centre of Radiotherapy, National Institute of Oncology, Rath Gyorgy St. 7-9, 
      1122, Budapest, Hungary.
AD  - Department of Oncology, Semmelweis University, Budapest, Hungary.
FAU - Akiyama, Hironori
AU  - Akiyama H
AUID- ORCID: 0000-0003-2530-4302
AD  - Department of Oral Radiology, Osaka Dental University, Osaka, Japan.
FAU - Frohlich, Georgina
AU  - Frohlich G
AUID- ORCID: 0000-0001-6428-6536
AD  - Centre of Radiotherapy, National Institute of Oncology, Rath Gyorgy St. 7-9, 
      1122, Budapest, Hungary.
AD  - Faculty of Science, Eotvos Lorand University, Budapest, Hungary.
FAU - Oberna, Ferenc
AU  - Oberna F
AD  - Multidisciplinary Centre of Head and Neck Tumours, National Institute of 
      Oncology, Budapest, Hungary.
FAU - Revesz, Monika
AU  - Revesz M
AUID- ORCID: 0000-0001-5651-8536
AD  - Multidisciplinary Centre of Head and Neck Tumours, National Institute of 
      Oncology, Budapest, Hungary.
FAU - Poosz, Marton
AU  - Poosz M
AD  - Centre of Radiotherapy, National Institute of Oncology, Rath Gyorgy St. 7-9, 
      1122, Budapest, Hungary.
FAU - Polgar, Csaba
AU  - Polgar C
AUID- ORCID: 0000-0001-7245-0762
AD  - Centre of Radiotherapy, National Institute of Oncology, Rath Gyorgy St. 7-9, 
      1122, Budapest, Hungary.
AD  - Department of Oncology, Semmelweis University, Budapest, Hungary.
LA  - eng
PT  - Journal Article
DEP - 20220214
PL  - Germany
TA  - Strahlenther Onkol
JT  - Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et 
      al]
JID - 8603469
SB  - IM
MH  - *Brachytherapy/methods
MH  - Combined Modality Therapy
MH  - Humans
MH  - Margins of Excision
MH  - Radiotherapy Dosage
MH  - Retrospective Studies
MH  - *Tongue Neoplasms/radiotherapy/surgery
PMC - PMC9402734
OTO - NOTNLM
OT  - Brachytherapy
OT  - High-dose-rate
OT  - Postoperative treatment
OT  - Survival
OT  - Tongue neoplasms
COIS- Z. Takacsi-Nagy, O. Ferenczi, T. Major, H. Akiyama, G. Frohlich, F. Oberna, 
      M. Revesz, M. Poosz and C. Polgar declare that they have no competing interests.
EDAT- 2022/02/15 06:00
MHDA- 2022/08/27 06:00
PMCR- 2022/02/14
CRDT- 2022/02/14 12:16
PHST- 2021/08/17 00:00 [received]
PHST- 2022/01/16 00:00 [accepted]
PHST- 2022/02/15 06:00 [pubmed]
PHST- 2022/08/27 06:00 [medline]
PHST- 2022/02/14 12:16 [entrez]
PHST- 2022/02/14 00:00 [pmc-release]
AID - 10.1007/s00066-022-01901-w [pii]
AID - 1901 [pii]
AID - 10.1007/s00066-022-01901-w [doi]
PST - ppublish
SO  - Strahlenther Onkol. 2022 Sep;198(9):812-819. doi: 10.1007/s00066-022-01901-w. 
      Epub 2022 Feb 14.